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Purpose: The aim of this study was to describe the association between educational level and 
incident cardiovascular disease (CVD) and all-cause mortality in Hong Kong Chinese patients 
with type 2 diabetes.
Patients and methods: We included 12,634 patients with type 2 diabetes who were enrolled 
into the Joint Asia Diabetes Evaluation Program between June 1, 2007, and June 30, 2017. We 
classified patients’ educational level into the following three groups: ≤6 years, 6–13 years, and 
>13 years. Incident CVD events were identified using hospital discharge diagnoses. Death was 
identified from Hong Kong Death Register. We estimated HRs for incident CVD and all-cause 
mortality using Cox regression models.
Results: Patients with the highest educational level were younger and had shorter diabetes 
duration and better glycemic control at enrollment than those with the lowest educational level. 
During the median follow-up of 6.2 years for CVD and 6.4 years for all-cause mortality, 954 
CVD events and 833 deaths were recorded. HRs for CVD and all-cause mortality were 0.73 
(95% CI: 0.57, 0.94) and 0.71 (95% CI: 0.54, 0.94) for the highest educational level compared 
to the lowest educational level, after adjustment for age, sex, diabetes duration, and family 
history of diabetes.
Conclusion: Educational level is inversely associated with the risk of CVD and all-cause mortal-
ity among Hong Kong Chinese patients with type 2 diabetes. Hong Kong Chinese patients with 
type 2 diabetes and low educational level should be given special attention for the prevention 
of key complications of diabetes.
Keywords: socioeconomic status, educational level, diabetes, cardiovascular disease, all-cause 
mortality
Introduction
Cardiovascular disease (CVD) is one of the most common causes of morbidity and 
premature mortality in people with type 2 diabetes.1 Large cohort studies suggest that 
people with diabetes are at two- to fourfold increased risk of CVD events compared 
with nondiabetic populations.2 A review of data published between 1990 and 2010 
concluded that the risk of all-cause mortality among people with diabetes was approxi-
mately double those of the general population, although relative risks vary with age, 
sex, and socioeconomic status (SES).3,4
SES is an important determinant of people’s health.5 The explanations for the 
association of SES with health outcomes are multifactorial and include influences 
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on health care, health-related behaviors, and environmental 
factors.6 Inverse associations between SES and incident 
CVD in general populations7 and all-cause mortality in 
both general populations8,9 and people with diabetes4,10,11 
have previously been reported. However, there is limited 
information available about the association between SES and 
incident CVD in patients with type 2 diabetes, whose health-
related behaviors, treatment patterns, health surveillance, 
and the variation by SES may differ importantly from those 
of general populations.12 The effect of the epidemiological 
transition on changes in number and distribution of patients 
with type 2 diabetes means that more evidence is required 
to clarify the relationship between SES and complications of 
type 2 diabetes in populations in Asia and around the world, 
including countries at a different stage of the epidemiologi-
cal transition.13
In this study, we describe the association between edu-
cational level, one of the key measures of SES, and incident 
CVD and all-cause mortality in Hong Kong Chinese patients 
with type 2 diabetes using prospective data from the Joint 
Asia Diabetes Evaluation (JADE) program.
Patients and methods
Study population
The rationale, design, and implementation of the JADE 
program have been published previously.14 Briefly, the JADE 
program is a disease management program implemented 
using an electronic portal that systematically captures clinical 
characteristics, including risk factors and complications, of 
patients with diabetes to create a diabetes register with built 
in risk engines to generate a personalized report with deci-
sion support. The JADE program was established in 2007 and 
enrolled patients diagnosed with diabetes from three public 
hospital-based diabetes centers, one public community-based 
clinic, and one university-affiliated self-funded nurse-led dia-
betes center in Hong Kong. Between June 1, 2007, and June 
30, 2017, 18,493 Hong Kong Chinese patients were enrolled 
in the JADE program. For our study, we excluded 4,155 
patients with baseline prevalent CVD. We further excluded 
324 patients with type 1 diabetes and included patients with 
unspecified diabetes under the assumption that most of these 
patients would have type 2 diabetes. We also excluded 1,380 
patients with missing data, leaving 12,634 patients (217 
patients with unspecified diabetes) for the present analyses 
(Figure S1). This study was approved by the Clinical Research 
Ethnics Committee of the Chinese University of Hong Kong 
and the relevant institutional boards of participating sites. All 
patients provided written informed consent.
Measures
All patients underwent comprehensive assessment guided by 
structured assessment forms including recording of sociode-
mographic factors, lifestyle factors, medical history, current 
medication use, physical examination, and laboratory testing 
based on the JADE protocol at enrollment.15 We classified 
patients’ educational level into the following three groups 
using years of education completed by an individual: ≤6 
years (primary school or below), 6–13 years (middle or high 
school), and >13 years (university or above). Information on 
incident CVD was identified using the principal diagnosis on 
hospital discharge records as coded by ICD-9 from the Hong 
Kong Hospital Authority (HA) Central Computer System. 
The HA is the governing body of all public-funded hospitals 
and outpatient clinics in Hong Kong. Clinical information on 
patients attending public hospitals and clinics is continuously 
recorded by the HA Central Computer System. Health care 
in Hong Kong is heavily subsidized, and as such, majority 
of the Hong Kong people seek care for acute and chronic 
illnesses in the public sector. It is estimated that about 95% 
of the total hospital bed days and 80% of the outpatient visits 
in Hong Kong occur in the public sector.16 Information on 
death was identified from linkage to the Hong Kong Death 
Register where cause of death is identified by ICD-9 codes.
For our analyses, CVD included any coronary heart 
disease (ICD-9 codes 410–414, and procedure codes 36 and 
00.66), congestive heart failure (ICD-9 code 428), stroke 
(ICD-9 codes 430–438), and peripheral vascular disease 
(ICD-9 codes 250.7, 785.4, 443.81, and 443.9 and procedure 
codes 39.29, 39.90, and 84.1 without ICD-9 codes 895–897).
Entry date to the cohort was the date when patients were 
enrolled into the JADE program. Exit date for CVD analyses 
was the date of the first incident, CVD event or June 30, 
2017, for patients who neither died nor had a CVD event 
recorded by that date, with censoring at the date of death 
where appropriate. Exit date for mortality analyses was the 
date of death or June 30, 2017, for survivors to that date. 
Follow-up time was calculated as the period from entry date 
to exit date or to censoring.
Statistical analyses
We described baseline characteristics of patients by educa-
tional level. One-way ANOVA, Kruskal–Wallis test, and Chi-
squared test were used for comparisons as appropriate. We 
used Cox proportional hazards models to estimate the HRs 
and 95% CIs for the association between educational level 
and incident CVD and all-cause mortality, adjusting for age 
at the diagnosis of diabetes and sex in model 1 and further 
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adjusting for family history of diabetes and diabetes duration 
at enrollment in model 2 forming the basic model. Potential 
mediating variables were selected based on a prior knowl-
edge of underlying mechanism linking SES and CVD and 
all-cause mortality.17 We created several further non-nested 
models in order to investigate the potential mediating roles 
separately for health-related behaviors, treatment received, 
baseline prevalent comorbidities, and metabolic risk factors 
between educational level and CVD and all-cause mortality 
and compare their contributions. Health-related behaviors 
(current smoking, regular use of alcohol, regular physical 
activity, and good adherence to balanced diet) were added 
to model 2 to create model 3. For model 4, we added current 
treatment (regular medical follow-up, record of attending 
diabetes education, use of oral antidiabetic drugs, insulin, 
antihypertensive drugs, and lipid-lowering drugs) to model 
2. Baseline prevalent comorbidities (albuminuria, diabetic 
retinopathy, sensory neuropathy, end-stage renal disease, 
chronic kidney disease, and cancer) were added to create 
model 5. Model 6 included baseline metabolic risk factors 
(body mass index, waist-to-hip ratio, SBP, DBP, hemoglobin 
A1c [HbA1c], fasting plasma glucose, low-density lipopro-
tein cholesterol, high-density lipoprotein cholesterol, and 
triglyceride). Finally, all variables were included in model 7. 
We checked the Cox proportional hazards assumption using 
Schoenfeld residuals and found no evidence of violation.
We performed likelihood ratio tests for models includ-
ing interaction terms to test whether age at the diagnosis of 
diabetes (<50 and ≥50 years), sex, and diabetes duration (<7 
and ≥7 years) modified the association between educational 
level and incident CVD or all-cause mortality. Potential effect 
modifiers were selected based on previous studies reporting 
interactions between age, sex, and duration of diabetes and 
SES on CVD and all-cause mortality.4,18 We used compet-
ing risk regression models19 to estimate the subdistribution 
HRs (sHRs), with death not due to CVD as the competing 
risk. We compared the characteristics of patients with and 
without complete data. We performed a sensitivity analysis 
after excluding patients with unspecified diabetes. Statistical 
analyses were conducted using the R software (Version 3.3.3).
Results
Characteristics of patients
Among 12,634 patients included in the analyses, 47.7% were 
women, 11.3% were in the highest educational category 
(>13 years), and 41.4% were in the lowest educational category 
(≤6 years). The mean (SD) age was 50.9 (10.9) years at the 
diagnosis of diabetes and was 59.2 (10.1) years at  enrollment. 
Compared with patients with the lowest educational level, 
those with the highest educational level were younger at the 
diagnosis of diabetes (mean 48.7 vs 54.2 years) and had shorter 
diabetes duration (median 5.0 vs 8.0 years), including higher 
proportions of men (72.1 vs 37.6%) and patients with a family 
history of diabetes (68.7 vs 49.3%) (Table 1). About 39.2 and 
44.0% of patients with the highest educational level were cur-
rent alcohol drinkers and engaged in regular physical activity, 
while the proportions of those with the lowest educational level 
were 24.2 and 52.4%, respectively. Patients with the highest 
educational level had lower prevalence of comorbidities. 
For example, the prevalence of diabetic retinopathy, sensory 
neuropathy, chronic kidney disease, albuminuria, and cancer 
was 18.1, 2.9, 11.0, 29.1, and 4.8%, respectively, in patients 
with the highest educational level, while the prevalence of 
diabetic retinopathy, sensory neuropathy, chronic kidney 
disease, albuminuria, and cancer was 29.1, 5.8, 22.2, 40.5, 
and 7.2%, respectively, in those with the lowest educational 
level. In addition, patients with the highest educational level 
were less likely to receive regular medical follow-up, received 
diabetes education, insulin, antihypertensive drugs, and lipid-
lowering drugs, and had better metabolic risk factors’ patterns 
at enrollment than patients with the lowest educational level. 
For patients with the highest educational level, the mean SBP 
and HbA1c were 130.3 mmHg and 56.9 mmol/mol, respec-
tively, and 74.5% had prevalent hypertension. For patients with 
the lowest educational level, the mean SBP and HbA1c were 
137.5 mmHg and 59.1 mmol/mol, respectively, and 83.4% 
had prevalent hypertension. There were statistically significant 
differences in several characteristics between patients with and 
without complete data, but the absolute differences were very 
small (Table S1).
Association between educational level 
and incident CVD and all-cause mortality
During the median (IQR) follow-up of 6.2 (4.3–7.2) years 
for CVD and 6.4 (4.4–7.3) years for all-cause mortality, 
954 incident CVD events and 833 deaths were recorded, 
with crude CVD and mortality rates 12.9 and 10.9/1,000 
person-years respectively. The number of events, duration 
of follow-up, and event rates by educational level is shown 
in Table 2. The Kaplan–Meier curves for incident CVD and 
all-cause mortality by educational level are shown in Figure 1.
After adjusting for age at diabetes diagnosis, sex, diabetes 
duration, and family history of diabetes, an inverse associa-
tion consistent with a dose–response pattern was observed 
both between educational level and incident CVD and 
between educational level and all-cause mortality (Table 3). 
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The adjusted HRs for incident CVD and all-cause mortality 
were 0.73 (95% CI: 0.57, 0.94) and 0.71 (95% CI: 0.54, 0.94), 
respectively, for the highest educational level compared to the 
lowest educational level. The strength of both associations 
was attenuated after further adjustment for health-related 
behaviors, current treatment, baseline prevalent comor-
bidities, or baseline metabolic risk factors, with baseline 
prevalent comorbidities and metabolic risk factors making 
the largest contributions (Table 3). The competing risk regres-
sion models obtained similar results to the Cox proportional 
hazards models, indicating little evidence for an important 
Table 1 Characteristics of patients (n=12,643) according to educational level
Variables Education (years of education)
≤6 (n=5,232) 6–13 (n=5,974) >13 (n=1,428)
Age at the diagnosis of diabetes (years) 54.2 (11.0) 48.7 (10.1) 48.7 (10.3)
Age at enrollment (years) 63.6 (9.4) 56.2 (9.2) 55.7 (10.1)
Women 3,265 (62.4) 2,360 (39.5) 398 (27.9)
Diabetes duration (years), median (IQR) 8.0 (3.0–14.0) 5.5 (2.0–12.0) 5.0 (1.0–11.0)
Family history of diabetes 2,577 (49.3) 3,856 (64.5) 981 (68.7)
Health-related behaviors
Current smoking 536 (10.2) 780 (13.1) 125 (8.8)
Current use of alcohol 1,268 (24.2) 2,118 (35.5) 560 (39.2)
Regular physical activity (≥3 times/week) 2,743 (52.4) 2,588 (43.3) 629 (44.0)
Good adherence to balanced diet 2,819 (53.9) 3,042 (50.9) 729 (51.1)
Treatment
Regular medical follow-up (≥1 time/year) 5,104 (97.6) 5,717 (95.7) 1,338 (93.7)
Diabetes education 3,951 (75.5) 4,341 (72.7) 964 (67.5)
Oral antidiabetic drugs 4,529 (86.6) 5,104 (85.4) 1,202 (84.2)
Insulin 1,270 (24.3) 1,220 (20.4) 261 (18.3)
Antihypertensive drugs 3,410 (65.2) 3,289 (55.1) 775 (54.3)
Lipid-lowering drugs 2,440 (46.6) 2,566 (43.0) 643 (45.0)
Baseline prevalent comorbidities
Diabetic retinopathy 1,520 (29.1) 1,460 (24.4) 259 (18.1)
Sensory neuropathy 302 (5.8) 198 (3.3) 42 (2.9)
Chronic kidney disease 1,161 (22.2) 762 (12.8) 157 (11.0)
End-stage renal disease 63 (1.2) 57 (1.0) 15 (1.1)
Albuminuria 2,121 (40.5) 2,019 (33.8) 416 (29.1)
Cancer 375 (7.2) 310 (5.2) 68 (4.8)
Metabolic risk factors
BMI (kg/m2) 25.7 (4.2) 25.9 (4.3) 26.2 (4.4)
Waist circumference (men) (cm) 90.9 (10.4) 91.0 (10.6) 92.0 (10.6)
Waist circumference (women) (cm) 86.8 (10.7) 85.9 (11.0) 85.5 (11.2)
Waist-to-hip ratio (men) 0.96 (0.07) 0.95 (0.06) 0.94 (0.06)
Waist-to-hip ratio (women) 0.91 (0.07) 0.89 (0.07) 0.88 (0.07)
SBP (mmHg) 137.5 (18.7) 132.6 (17.6) 130.3 (16.6)
DBP (mmHg) 77.2 (10.3) 78.9 (10.6) 78.6 (10.1)
Hypertensiona 4,366 (83.4) 4,552 (76.2) 1,064 (74.5)
HbA1c% (mmol/mol) 7.56 (59.1) 7.53 (58.8) 7.36 (56.9)
Fasting plasma glucose (mmol/L) 7.82 (2.55) 7.85 (2.51) 7.77 (2.41)
HDL cholesterol (mmol/L) 1.36 (0.37) 1.31 (0.35) 1.28 (0.36)
LDL cholesterol (mmol/L) 2.68 (0.84) 2.69 (0.88) 2.64 (0.86)
Triglycerides (mmol/L) 1.50 (0.90) 1.55 (1.01) 1.60 (0.99)
Notes: Data are mean (SD) or n (%), unless otherwise indicated. aHypertension defined as SBP ≥130 or DBP ≥80 or taking antihypertensive drugs.
Abbreviations: BMI, body mass index; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
effect of competing risk from non-CVD death (Table S2). 
The only evidence for interaction we identified was that the 
association of educational level with all-cause mortality 
was more pronounced in patients aged less than 50 years 
(Table S3). The sensitivity analysis excluding patients with 
unspecified diabetes had little effect on the results (data not 
shown but are available from authors).
Discussion
In this large prospective cohort study, we found a clear 
socioeconomic gradient in two key health outcomes in a 
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contemporary cohort of Hong Kong Chinese patients with 
type 2 diabetes, with higher educational level being associ-
ated with a decreased risk of CVD and all-cause mortality. 
Diabetes-related comorbidities and metabolic risk factors 
made major contributions to the observed disparities.
To the best of our knowledge, this is the first prospective 
cohort study to describe the association between SES and 
incident CVD in Hong Kong Chinese with type 2 diabetes. 
A prospective study of 11,140 participants with type 2 dia-
betes and aged 55 years or older from 20 countries reported 
that people with low educational level had 31% (95% CI: 
16, 48%) of increased risk of vascular events than those 
with high educational level during a median follow-up of 
5 years.20 Several studies also reported that educational 
level was inversely associated with incident CVD in type 1 
Table 2 Duration of follow-up and CVD and all-cause mortality rates according to educational level (n=12,634)
Events Education (years of education)
≤6 (n=5,232) 6–13 (n=5,974) >13 (n=1,428)
Incident CVD
Number of events 502 374 78
Number of person-years 30,173 35,141 8,420
Crude event rate (number/1,000 person-years) 16.6 10.6 9.3
Age- and sex-standardizeda event rate (number/1,000 person-years) 17.4 10.8 8.9
All-cause mortality
Number of events 487 288 58
Number of person-years 31,534 36,175 8,691
Crude event rate (number/1,000 person-years) 15.4 8.0 6.7
Age- and sex-standardizeda event rate (number/1,000 person-years) 14.4 8.1 7.4
Notes: aTotal population included in the analysis by age at diabetes diagnosis (quartiles) and sex is used as the standard population.
Abbreviation: CVD, cardiovascular disease.
Figure 1 Kaplan–Meier curves for incident CVD (A) and all-cause mortality (B) by educational level.
Abbreviation: CVD, cardiovascular disease.
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 diabetes.21,22 Given the scarcity of similar data in type 2 dia-
betes, our results suggest that Hong Kong Chinese patients 
with type 2 diabetes, especially those less than 50 years old, 
who have a low educational level may require special atten-
tion, eg, diabetes education and ongoing support, although 
trials will be needed to test the effectiveness of targeted 
interventions. In the general Hong Kong Chinese population, 
SES was positively associated with CVD mortality before 
1990, but this association was reversed in later year.23–25 This 
epidemiological transition is consistent with patterns in other 
countries where greater burden of noncommunicable diseases 
initially occurs in people with high SES but later shifts toward 
people with lower SES following economic development and 
urbanization.26 However, due to the lack of data of patients 
from earlier periods, we are not able to explore whether the 
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association between educational level and risk of CVD and 
all-cause mortality among patients with type 2 diabetes in 
Hong Kong has changed over time.
The observed socioeconomic inequalities in CVD and all-
cause mortality were consistent for men and women and for 
patients with different diabetes duration. However, we found 
the beneficial effect of educational level on all-cause mortality 
appeared to be more pronounced in younger patients, similar 
to other studies.4,27 With increasing age, biological factors may 
contribute more than socioeconomic factors to determine 
the health.28 Besides, after retirement, there are often greater 
reductions in some psychosocial risk factors in patients with 
low SES, such as occupational stress.29 In contrast, in young 
patients, lack of awareness or concern of long-term impacts 
of chronic disease such as diabetes, competing priorities, 
and psychosocial factors may interact with socioeconomic 
differentials to increase the long-term disease burden.
Various models have been proposed to explain socioeco-
nomic inequalities in health.9,17,30 Health-related behaviors, 
access to health care, and processes of care are considered to 
be the main mechanisms linking SES and health outcomes 
among patients with diabetes.17 Generally, patients with 
low SES in more developed countries have worse patterns 
Table 3 HRs for incident CVD and all-cause mortality according to educational level in models including different covariates (n=12,634)
Cox models Education (years of education)
≤6 (reference) 6–13 >13
HR HR (95% CI) HR (95% CI) P-value for trend
Incident CVD
Model 1 1 0.63 (0.55, 0.73) 0.53 (0.41, 0.67) <0.001
Model 2 1 0.87 (0.75, 1.00) 0.73 (0.57, 0.94) 0.006
Model 3 1 0.90 (0.78, 1.04) 0.79 (0.62, 1.01) 0.041
Model 4 1 0.88 (0.76, 1.02) 0.75 (0.59, 0.97) 0.015
Model 5 1 0.90 (0.78, 1.05) 0.80 (0.62, 1.03) 0.052
Model 6 1 0.92 (0.80, 1.07) 0.84 (0.65, 1.07) 0.13
Model 7 1 0.97 (0.83, 1.12) 0.92 (0.71, 1.18) 0.48
All-cause mortality
Model 1 1 0.61 (0.52, 0.71) 0.49 (0.37, 0.65) <0.001
Model 2 1 0.89 (0.76, 1.05) 0.71 (0.54, 0.94) 0.014
Model 3 1 0.92 (0.79, 1.08) 0.75 (0.57, 0.99) 0.051
Model 4 1 0.93 (0.79, 1.08) 0.75 (0.57, 0.99) 0.050
Model 5 1 0.94 (0.81, 1.11) 0.78 (0.59, 1.04) 0.11
Model 6 1 0.93 (0.79, 1.09) 0.79 (0.59, 1.05) 0.10
Model 7 1 0.98 (0.84, 1.15) 0.88 (0.66, 1.17) 0.46
Notes: Model 1: adjusted for age and sex. Model 2: adjusted for age, sex, diabetes duration, and family history of diabetes. Model 3: model 2+ health behaviors (including 
smoking, use of alcohol, physical activity, and adherence to balanced diet). Model 4: model 2+ treatment (including regular medical follow-up, diabetes education, oral 
antidiabetic drugs, use of insulin, antihypertensive drugs, and lipid regulating drugs). Model 5: model 2+ baseline prevalent comorbidities (including cancer, albuminuria, 
diabetic retinopathy, sensory neuropathy, end-stage renal disease, and chronic kidney disease). Model 6: model 2+ baseline metabolic risk factors (including body mass index, 
waist-to-hip ratio, SBP, DBP, hemoglobin A1c, fasting blood glucose, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides). Model 7: 
adjusted for all variables listed above.
Abbreviation: CVD, cardiovascular disease.
of health-related behaviors and less access to health care 
and are less likely to receive important processes of care. 
However, in Hong Kong, all citizens had access to highly 
subsidized care where integrated team-based diabetes care, 
with nurse-coordinated diabetes centers, is available to most 
hospitals.31 Indeed, patients with low educational level had 
better patterns of health-related behaviors with more regular 
medical follow-up and higher rates of treatments for diabe-
tes, hypertension, and dyslipidemia at enrollment. However, 
these patients were older at diabetes diagnosis and had longer 
diabetes duration, which might contribute to higher preva-
lence of comorbidities, poorer metabolic control, and greater 
requirement for medications and health care at baseline. In 
addition, longer diabetes duration potentially gives patients 
more opportunities to receive diabetes education, which 
could result in an improvement of health-related behaviors 
that may help improve the natural history of the condition. 
In contrast, patients with lower educational level may have 
lower health awareness with delayed presentation and older 
age of diagnosis than patients with higher educational level.32 
Despite the availability of comprehensive assessment, non-
adherence to appointment may be a contributing factor to the 
longer diabetes duration at enrollment to the JADE program 
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in patients with lower educational level compared to those 
with higher educational level.
We found that baseline diabetes-related comorbidities and 
metabolic risk factors were more common among patients 
with low educational level. The effect of educational level 
on CVD and mortality was largely attenuated after adjust-
ment for either diabetes-related comorbidities or metabolic 
risk factors. This finding suggests that educational level 
is likely to affect the risk of CVD and all-cause mortality 
through the association with diabetes-related comorbidities 
and metabolic risk factors. This information is a key for 
clinical management of patients with type 2 diabetes. There 
is conclusive evidence showing that lower rates of diabetes-
related comorbidities and attaining multiple metabolic targets 
could effectively reduce CVD risk and mortality in type 2 
diabetes.33–36 Therefore, health care and social policies aimed 
at reducing socioeconomic inequalities in CVD and all-cause 
mortality in type 2 diabetes should prioritize the control of 
diabetes-related comorbidities and metabolic risk factors 
among younger individuals with low educational level. 
Though interventions at the individual level can be expected 
to have beneficial effects on health outcomes, policies are also 
needed to address the upstream determinants of health such 
as education. Our study highlights the potential importance of 
universal education that may have long-term health impacts.
Strengths and limitations 
Our study has some limitations. Educational attainment is 
only one component of a person’s SES. Different measures of 
SES may have different effects on people’s health outcomes 
and through different mechanisms.32 However, information 
on other measures of SES other than educational level was not 
available in our database. We were not able to investigate the 
effects of other SES measures on the risk of CVD and all-cause 
mortality such as income and area-based measures of SES and 
whether the effects of educational level on the risk of CVD and 
all-cause mortality were independent of other SES measures. 
In addition, we have included patients with prevalent diabetes 
at enrollment to the JADE program in the analyses and have 
therefore excluded patients who died before having the oppor-
tunity to enroll in the JADE program. If, as expected, patients 
with lower educational level were more likely to be excluded 
for this reason than patients with higher educational level, the 
inverse association between educational level and all-cause 
mortality is likely to have been underestimated. Furthermore, 
a single time-point assessment of health-related behaviors 
and metabolic risk factors at enrollment might not be sensi-
tive enough to measure their cumulative effects on long-term 
health outcomes or to investigate potential interactions with 
SES. Finally, patients enrolled in the JADE program may not 
be representative of the Hong Kong Chinese patients with 
diabetes, younger mean age at the diagnosis of diabetes, and 
lower proportion of women in the JADE database compared 
to patients with diabetes identified from public sector health 
records.37 It is possible that socioeconomic differences observed 
in our study are greater than those in all Hong Kong Chinese 
with diabetes, given the narrowing of inequalities in older age.
Despite these limitations, this study has several strengths. 
The outcome ascertainment in our study was complete, and 
accuracy of recording is unlikely to differ markedly by edu-
cational level. Due to the universal and equitable health care 
systems in Hong Kong, access to public hospitals and clinics 
is less likely to be affected by SES or people’s payment abil-
ity.38 Data from our study have showed that more than 97% 
of patients reported having regular medical follow-up more 
than once a year at enrollment, indicating that socioeconomic 
difference in CVD ascertainment in our population was 
unlikely. In addition, we had comprehensive demographic 
and clinical data of patients at baseline, which enabled us to 
explore various potential pathways linking educational level 
and risk of CVD and all-cause mortality.
Conclusion
Using data from the JADE program, we have shown that 
educational level is inversely associated with the risk of 
CVD and all-cause mortality among Hong Kong Chinese 
patients with type 2 diabetes. Hong Kong Chinese with type 
2 diabetes and low educational level should be given special 
attention for the prevention of key complications of diabetes.
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Supplementary materials
Table S1 Characteristics of patients with (n=12,634) and without (n=14,014) complete data: Hong Kong, 2007–2017
Variables Participants with complete  
data (n=12,634)
Participants without  
complete data (n=14,014)
Age at diagnosis of diabetes (years) 50.9 (10.9) 50.9 (10.9)
Age at enrollment (years) 59.2 (10.1) 58.2 (11.4)
Women 6,023 (47.7) 6,700 (47.8)
Diabetes duration (years), median (IQR) 6.0 (2–13) 6.0 (2–13)
Educational level
≤6 years 5,232 (41.4) 5,603 (40.1)
>6 and ≤13 years 5,974 (47.3) 6,661 (47.7)
3 years 1,428 (11.3) 1,698 (12.2)
Family history of diabetes 7,414 (58.7) 8,207 (58.6)
Health-related behaviors
Current smoking 1,441 (11.4) 1,663 (11.9)
Current use of alcohol 3,946 (31.2) 4,405 (31.5)
Regular physical activity (≥3 times/week) 5,960 (47.2) 6,386 (45.7)
Good adherence to balanced diet 6,590 (52.2) 7,274 (52.0)
Treatment
Regular medical follow-up (≥1 time/year) 12,159 (96.2) 13,380 (95.6)
Diabetes education 9,256 (73.3) 10,288 (73.6)
Oral antidiabetic drugs 10,835 (85.8) 11,854 (84.6)
Insulin 2,751 (21.8) 3,092 (22.1)
Antihypertensive drugs 7,474 (59.2) 8,081 (57.7)
Lipid-lowering drugs 5,649 (44.7) 6,079 (43.4)
Baseline prevalent comorbidities
Diabetic retinopathy 3,239 (25.6) 3,537 (25.4)
Sensory neuropathy 542 (4.3) 583 (4.2)
Chronic kidney disease 2,080 (16.5) 2,289 (16.3)
End-stage renal disease 135 (1.1) 167 (1.2)
Albuminuria 4,556 (36.1) 4,974 (36.2)
Cancer 753 (6.0) 815 (5.8)
Metabolic risk factors
BMI (kg/m2) 25.9 (4.2) 26.0 (4.4)
Waist circumference (men) (cm) 91.1 (10.5) 91.2 (10.7)
Waist circumference (women) (cm) 86.4 (10.9) 86.4 (11.1)
Waist-to-hip ratio (men) 0.95 (0.06) 0.95 (0.07)
Waist-to-hip ratio (women) 0.90 (0.07) 0.90 (0.07)
SBP (mmHg) 134.4 (18.1) 134.0 (18.2)
DBP (mmHg) 78.2 (10.4) 78.1 (10.5)
Hypertensiona 9,982 (79.0) 10,900 (77.8)
HbA1c% (mmol/mol) 7.53 (58.8) 7.55 (59.0)
Fasting plasma glucose (mmol/L) 7.83 (2.52) 7.86 (2.60)
HDL cholesterol (mmol/L) 1.33 (0.36) 1.32 (0.37)
LDL cholesterol (mmol/L) 2.68 (0.86) 2.69 (0.87)
Triglycerides (mmol/L) 1.54 (0.96) 1.63 (1.46)
Notes: Data are mean (SD) or n (%), unless otherwise indicated. Missing data for participants without complete data were 667 for age at the diagnosis of diabetes, 1 for age 
at enrollment, 667 for diabetes duration, 4 for smoking, 8 for the use of alcohol, 42 for regular physical activity, 30 for good adherence to balanced diet, 12 for regular medical 
follow-up, 39 for diabetes education, 12 for antihypertensive drugs, 10 for lipid lowering drugs, 104 for diabetic retinopathy, 4 for sensory neuropathy, 280 for albuminuria, 24 
for BMI, 25 for waist circumference, 33 for waist-to-hip ratio, 6 for SBP, 6 for DBP, 5 for hypertension, 25 for HbA1c, 57 for fasting plasma glucose, 62 for HDL cholesterol, 
265 for LDL cholesterol, 53 for triglycerides. aHypertension defined as SBP ≥130 or DBP ≥80 or taking antihypertensive drugs.
Abbreviations: BMI, body mass index; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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Table S2 Subdistribution HRs for incident CVD according to educational level (n=12,634): Hong Kong, 2007–2017
Subdistribution HRs Education (years of education) 
≤6 (reference) 6–13 >13
sHR sHR (95% CI) sHR (95% CI)
Model 1 1 0.64 (0.55, 0.74) 0.53 (0.42, 0.68)
Model 2 1 0.86 (0.75, 1.01) 0.74 (0.58, 0.94)
Model 3 1 0.90 (0.77, 1.04) 0.79 (0.62, 1.02)
Model 4 1 0.88 (0.76, 1.03) 0.76 (0.59, 0.97)
Model 5 1 0.90 (0.78, 1.05) 0.80 (0.62, 1.03)
Model 6 1 0.92 (0.79, 1.07) 0.83 (0.65, 1.07)
Model 7 1 0.96 (0.82, 1.11) 0.91 (0.71, 1.17)
Notes: Model 1: adjusted for age and sex. Model 2: adjusted for age, sex, diabetes duration, and family history of diabetes. Model 3: model 2+ health behaviors (including 
smoking, use of alcohol, physical activity, and adherence to balanced diet). Model 4: model 2+ treatment (including regular medical follow-up, diabetes education, oral 
antidiabetic drugs, use of insulin, antihypertensive drugs, and lipid-regulating drugs). Model 5: model 2+ baseline prevalent comorbidities (including cancer, albuminuria, 
diabetic retinopathy, sensory neuropathy, end-stage renal disease, and chronic kidney disease). Model 6: model 2+ baseline metabolic risk factors (body mass index, waist-
to-hip ratio, SBP, DBP, hemoglobin A1c, fasting blood glucose, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides). Model 7: adjusted 
for all variables listed above.
Abbreviations: CVD, cardiovascular disease; sHR, subdistribution HR.
Table S3 HRs for incident CVD and all-cause mortality according to educational level in strata for age, sex, and diabetes duration: 
Hong Kong, 2007–2017
Subgroups Education (years of education) 
≤6 (reference) 6–13 >13
HR HR (95% CI) HR (95% CI) P-value for interaction
Incident CVD
Age at diagnosis of diabetes (years)
<50 1 0.84 (0.67, 1.05) 0.62 (0.42, 0.91) 0.19
≥50 1 0.69 (0.57, 0.84) 0.68 (0.50, 0.95)
Sex
Men 1 0.81 (0.67, 0.97) 0.71 (0.54, 0.95) 0.78
Women 1 1.00 (0.79, 1.27) 0.69 (0.40, 1.22)
Diabetes duration (years)
<7 1 0.82 (0.64, 1.04) 0.64 (0.42, 0.97) 0.89
≥7 1 0.73 (0.61, 0.87) 0.65 (0.47, 0.88)
All-cause mortality
Age at diagnosis of diabetes (years)
<50 1 0.85 (0.64, 1.12) 0.35 (0.18, 0.66) 0.008
≥50 1 0.63 (0.52, 0.77) 0.69 (0.51, 0.94)
Sex
Men 1 0.93 (0.76, 1.13) 0.73 (0.53, 1.01) 0.41
Women 1 0.85 (0.64, 1.12) 0.65 (0.35, 1.24)
Diabetes duration (years)
<7 1 0.81 (0.63, 1.06) 0.67 (0.43, 1.06) 0.96
≥7 1 0.73 (0.60, 0.89) 0.59 (0.41, 0.84)
Note: All models were adjusted for age at the diagnosis of diabetes, sex (as appropriate), diabetes duration, and family history of diabetes.
Abbreviation: CVD, cardiovascular disease.
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Figure S1 Selection of patients for investigation of the association between educational level and incident CVD or all-cause mortality: Hong Kong, 2007–2017.
Abbreviation: CVD, cardiovascular disease.
14,014 patients with type 2 diabetes or unspecific diabetes
14,338 patients without baseline prevalent CVD
4,155 patients with baseline prevalent CVD excluded
324 patients with type 1 diabetes excluded
12,634 patients with type 2 diabetes or
unspecific diabetes (n=217), without baseline
prevalent CVD and with complete data
1,380 patients with missing data excluded
18,493 patientsenrolled in JADE Program between June 1, 
2007, and June 30, 2017
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